Benitec Biopharma recorded $51,192 thousand in total operating expenses for the year ended June 30, 2026, while Research and Development costs reached $23.4 million. Investors face a stated outlook for potentially higher R&D spending, along with increased accounting, legal, regulatory and director and officer insurance costs.

Key Highlights

  • Research and development spending reached $23.4 million, compared with $18.3 million for the comparable year.
  • Common stock issuance generated $104.5 million before $5.7 million of underwriter costs and $0.6 million of other incidental costs.
  • Operating Lease liabilities stood at $762,000 in the reported US$000 table at June 30, 2026.

Benitec Biopharma Inc. (NASDAQ: BNTC) recorded $51,192 thousand in total operating expenses for the year ended June 30, 2026. The company generated or recognized no Revenue during the year. The outlook places expense growth alongside the company’s ongoing clinical development spending. Benitec Biopharma also identified higher compliance-related services and other similar costs as areas of potential increase.

Fiscal-Year Expense Breakdown

General and administrative expenses were $27,804 thousand, compared with $23,433 thousand. The company’s total operating expenses were $41,765 thousand for the comparable year. The reported expenses included research and development and general and administrative expenses during the year ended June 30, 2026. Common stock issuance generated $104.5 million. Underwriter issuance costs were $5.7 million, while other incidental costs were $0.6 million.

Compensation Drove R&D Increase

A reduction in contract Manufacturing costs partly offset those increases. The company records estimated costs for research and development activities, including work performed by third-party service providers and contract manufacturing activities. The company anticipated increases in certain expenses.

Cash Risk And Lease Commitments

The company identified concentration of Credit risk related primarily to cash. Operating lease liabilities stood at $762,000 in the reported US$000 table at June 30, 2026, including a current portion of $496,000 and a non-current portion of $266,000. The weighted average lease term was 1.45 years, and the weighted average discount rate was 0.06%. The company reported total operating lease payments of $796,000, less Imputed Interest of $34,000. Payments listed for 2027 were $526,000 and for 2028 were $270,000. Benitec Biopharma’s authorized preferred stock totaled 5,000,000 shares, with a Par Value of $0.0001 per share. No Preferred Shares were issued and outstanding at June 30, 2026.